Prognostic Value of the C-Reactive Protein-albumin-lymphocyte Index For Patients With Recurrent οr Metastatic Head and Neck Squamous Cell Carcinoma Treated With Nivolumab.

IF 1.7 4区医学 Q4 ONCOLOGY

Anticancer research Pub Date : 2025-09-01 DOI:10.21873/anticanres.17757

Fumihiko Sato, Takeharu Ono, Akira Hiraki, Tsunehiro Oka, Toshiyuki Mitsuhashi, Masayasu Naito, Mioko Fukahori, Shintaro Sueyoshi, Itaru Mizobe, Masahiro Seki, Kiminobu Sato, Toshihiko Kawaguchi, Hisaichiro Tanaka, Takashi Kurita, Shun-Ichi Chitose, Hirohito Umeno

{"title":"Prognostic Value of the C-Reactive Protein-albumin-lymphocyte Index For Patients With Recurrent οr Metastatic Head and Neck Squamous Cell Carcinoma Treated With Nivolumab.","authors":"Fumihiko Sato, Takeharu Ono, Akira Hiraki, Tsunehiro Oka, Toshiyuki Mitsuhashi, Masayasu Naito, Mioko Fukahori, Shintaro Sueyoshi, Itaru Mizobe, Masahiro Seki, Kiminobu Sato, Toshihiko Kawaguchi, Hisaichiro Tanaka, Takashi Kurita, Shun-Ichi Chitose, Hirohito Umeno","doi":"10.21873/anticanres.17757","DOIUrl":null,"url":null,"abstract":"Background/aim: Systemic inflammation, immunity, and nutrition-based prognostic indices (SIINBPIs) have been associated with cancer prognosis. This study evaluated their prognostic relevance in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with nivolumab.Patients and methods: We retrospectively analyzed 103 R/M HNSCC patients who received nivolumab. Pretreatment blood tests were used to calculate SIINBPIs including the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), high-sensitivity modified Glasgow Prognostic Score (HS-mGPS), and the C-reactive protein-albumin-lymphocyte (CALLY) index.Results: The CALLY index and performance status were identified as independent prognostic factors for overall survival (OS). Patients with a high CALLY index had better performance status and were more likely to receive subsequent chemotherapy. The CALLY index showed superior prognostic performance over other SIINBPIs.Conclusion: The CALLY index may serve as a useful and independent prognostic biomarker for R/M HNSCC patients undergoing nivolumab therapy, reflecting systemic status and predicting treatment outcomes.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 9","pages":"3993-4004"},"PeriodicalIF":1.7000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17757","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Systemic inflammation, immunity, and nutrition-based prognostic indices (SIINBPIs) have been associated with cancer prognosis. This study evaluated their prognostic relevance in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with nivolumab.

Patients and methods: We retrospectively analyzed 103 R/M HNSCC patients who received nivolumab. Pretreatment blood tests were used to calculate SIINBPIs including the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), high-sensitivity modified Glasgow Prognostic Score (HS-mGPS), and the C-reactive protein-albumin-lymphocyte (CALLY) index.

Results: The CALLY index and performance status were identified as independent prognostic factors for overall survival (OS). Patients with a high CALLY index had better performance status and were more likely to receive subsequent chemotherapy. The CALLY index showed superior prognostic performance over other SIINBPIs.

Conclusion: The CALLY index may serve as a useful and independent prognostic biomarker for R/M HNSCC patients undergoing nivolumab therapy, reflecting systemic status and predicting treatment outcomes.

查看原文本刊更多论文

c反应蛋白-白蛋白淋巴细胞指数对纳武单抗治疗的复发性(o)转移性头颈部鳞状细胞癌患者的预后价值。

背景/目的：系统性炎症、免疫和基于营养的预后指标（siinbpi）与癌症预后相关。本研究评估了nivolumab治疗复发或转移性头颈部鳞状细胞癌（R/M HNSCC）患者的预后相关性。患者和方法：我们回顾性分析了103例接受纳武单抗治疗的R/M HNSCC患者。采用预处理血液试验计算siinbpi，包括中性粒细胞与淋巴细胞比率（NLR）、血小板与淋巴细胞比率（PLR）、淋巴细胞与单核细胞比率（LMR）、高灵敏度改良格拉斯哥预后评分（HS-mGPS）和c反应蛋白-白蛋白淋巴细胞指数（CALLY）。结果：CALLY指数和表现状态被确定为总生存期（OS）的独立预后因素。CALLY指数高的患者表现状态较好，接受后续化疗的可能性较大。CALLY指数显示优于其他siinbpi的预后表现。结论：CALLY指数可作为接受纳沃单抗治疗的R/M HNSCC患者的有用且独立的预后生物标志物，反映全身状态并预测治疗结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.